Xinnate is currently not actively operating any expanded access programs. This is due to the nature of the diseases for which Xinnate is developing therapies, as well as the early stage of development of these products, as outlined below.

The investigational medicinal product, TCP25, is currently in clinical development for specific forms of Epidermolysis Bullosa (EB). Details of the clinical study(ies) are or will be available on ClinicalTrials.gov. Patients who may be eligible for study participation are encouraged to contact participating sites for further information.

At this time, expanded access outside the intended study population is not anticipated.